Happy New Year!

We hope 2016 has started off with a bang for everyone. It has certainly been a productive January for CLL Global. We hosted our semi-annual Alliance meeting, bringing together CLL experts from all over the world to discuss their latest research findings as well as planned and ongoing clinical trials. Additionally, we are looking forward to World Cancer Day on February 4. World Cancer Day is a global event whose aim is to raise cancer awareness, to increase levels of education about the disease, and to encourage individuals and governments to join the fight to eradicate the disease. Plans are also underway for our next patient education event to be held in conjunction with our production partners at Patient Power. This event will occur in May 2016 at Columbia University in New York. Check back with us as we finalize details and open registration. Participation in person and online is free and open to everyone.

CLL Global Alliance Meeting

Highlights

On January 15-16, 2016, CLL Global hosted our semi-annual Alliance meeting in Houston, Texas. The Alliance meetings provide a unique opportunity for the unhindered exchange of ideas and the development of collaborations among CLL experts from around the world. The focus of the January meeting was "How can our research accelerate the cure of CLL?". Included in the meeting were sessions on immunology, genetics, pathways and signaling, drug development, the complexity
in Milan, Italy, and Drs. Michael Keating and Zeev Estrov from MD Anderson Cancer Center in Houston, Texas (left to right), discuss the importance of the stromal environment in CLL.

Presentations highlighted several areas of relevance to CLL, including: 1) the role of viruses in cancer, 2) the recognition of the importance of what was once called "junk" DNA in regulating normal and abnormal cell function, 3) the recognition of the ever-increasing complexity of the immune system, how it prevents cancer, and how cancer evades it, 4) the development of novel targeted therapies that are revolutionizing treatment options for high-risk and relapsed/refractory CLL patients, and 5) other cancers, including melanoma and non-melanoma skin cancers that are prevalent in CLL patients, as well as mutations that are associated with disease clusters. The meeting ended with an exciting discussion of the development of vaccines against cancer that have the potential to transform treatment options in much the same way monoclonal antibodies have since the advent of rituximab. CLL Global is extremely appreciative of the time and effort shared by attendees. Their participation ensured that every meeting was successful and set the stage for ongoing efforts throughout the coming year.

Featured Video

CLL ASH 2015 News: An Expert's Review

Dr. William Wierda of MD Anderson Cancer Center shares his insights on the "tornado of research activity" out of ASH 2015 meeting (American Society of Hematology) and perspective on the latest news and research in the field of CLL

Ibrutinib Showing Positive Results in the Frontline Setting

Dr. Jan Burger discusses results from the RESONATE-2 trial examining ibrutinib versus chlorambucil in the frontline setting.

Quick Links

News
Mission
More About Us
Newly Diagnosed

If you have been recently diagnosed with CLL, you probably have questions.

Information about CLL

What are we doing to defeat CLL

List of CLL Specialists around the World
(Provided by ACOR)

THANK YOU FOR SUPPORTING US!

We are excited about the opportunities 2016 offers for continuing the rapid advances that are being made towards long term remissions and the possibility of finding a cure for CLL. Targeted therapies and new immunotherapies enable a personalized treatment approach as a real possibility for many patients, including high-risk and relapsed/refractory patients. This advance would not have been possible without the immense time and effort of clinicians and research scientists combined with the support of CLL patients and caregivers. We are extremely grateful to our donors who make our mission of abolishing CLL as a threat to patient life and health by so generously supporting CLL research.

Sincerely,

CLL Global Research Foundation

Click Here to Donate to CLL!

CLL Global Research Foundation
PO Box 301402, Unit 428 | Houston, TX 77230
www.cllglobal.org

STAY CONNECTED:

Like us on Facebook